Cancer Types Spotlight
- Bladder
- Bone
- Breast
- CNS/Brain
- Colon and Rectum
- Endocrine System
- Esophagus
- GYN (Non-Ovary)
- GYN (Ovary)
- Head and Neck
- HIV-Related Cancers
- Hodgkin's Lymphoma
- Kidney (Renal Cell)
- Leukemia
- Liver and Bile Duct
- Lung
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Non-Hodgkin's Lymphoma
- Pancreas
- Pediatric Cancers
- Prostate
- Rare Cancers
- Skin (Melanoma)
- Skin (Non-Melanoma)
- Soft-Tissue Sarcoma
- Stomach
- Testicle
Bisphosphonates and Bisphosphonate Induced Osteonecrosis
Oral and Maxillofacial Surgery Clinics of North America. 2007 Nov;19(4):487-498, Yoh Sawatari, Robert E. Marx
Bisphosphonate-induced osteonecrosis of the jaws is the correct term for this real drug complication that most dental practitioners face. All nitrogen-containing bisphosphonates pose a risk, which is related to the route of administration, the potency of the bisphosphonate, and the duration of use. Although intravenous bisphosphonate-induced osteonecrosis of the jaws is mostly permanent, most cases can be prevented or managed if they develop, with only a few cases requiring resection for resolution. Oral bisphosphonate-induced osteonecrosis of the jaws also can be prevented with knowledge of the risk level related to the duration of use and the C-terminal telopeptide blood test results. Most cases can be resolved with a drug holiday either spontaneously or via straightforward débridement.
